hello, and everyone. Doug, Thanks,
by $X.X XXXX. therapy business in more detail as As we which revenue CARMA just was underlying therapy Cell over well with which strong this mentioned, quarter up XX% our growth primarily quarter in of Doug very third strength the SPL $XX.X million cell saw of growth minute. third revenue related driven I'll grew total XX% was revenue, million, of the XXXX. This over in revenue into a dive of quarter as
sales represents are Just manufacture and as therapies clinical use, based of customers disposables whether of ex for sales ultimately to preclinical, cell-based using that COVID-related comparison as therapy platform or to in cell that's Despite reported background, or growth the given licenses commercial third quick a often human to a early-stage in programs. as a to the core a vivo be can year-over-year therapy platforms therapy that cell SPLs ExPERT dynamics, Instrument run use. precursor business quarter, in historical the first we difficult our act cell more in related exceeding rate. customers purchase purchases instruments
our about and SPLs pipeline So the our tied potential that's that in in Notably, are CapEx we've encouraging for speak. cell therapy so to customers talked in spending, terms of less also to future, area. burgeoning the
the revenue clinical business quarter. is particularly quarter ramping as therapy And in seen to a strong saw the our customers we're past, driven we we by our this from where dynamic performance have given the So cell fourth core weighted seeing trials. less that's
using drug discovery as quarter, strong for was disposables and Drug of after million, pharma. the notably antibodies, XXXX for third sales protein people and large was basis buyer discovery, quarter which work the but third the lockdowns the the and the on quarter. manufacturing platform sales discovery small over such an to molecule as transient are revenue absolute of drug X% monoclonal a to viral terms to back vectors, manufacturing customers up represents got such primarily Drug as in quarter made those of of slightly proteins, COVID. applications, vaccines was down instruments second over in of discovery, In $X.X discovery revenue the and production scale ExPERT reminder, smaller as
more versus business XX% a given segment of the a of saw also this of past cell that become over discovery years, in the representing comparison cell shift the and again more said, X of years, had has sequential our been well. challenged revenue cell excluding It's excluding quarter been over -- and therapy the we in consistent couple overall in revenue encouraged a representing environment. business strong had in towards smaller we as driven this quarter are discoveries over part that's with just difficult therapy. Ultimately, of mix The milestones. second So by by XX% that a past challenging revenue, drug year. drug That growth the revenue year-over-year therapy COVID also milestones more uptick discovery and we drug the mix,
traction. cautiously transaction cost quarter also for optimistic to the expand So million third million of over $X.X XXXX. in seem that to of gaining we're quarter from this efforts that impact we've of active of lower introductions centers customers years to in with multi-vial our We customers the PA past and couple had regarding per serve revenue made to have SPL the compared CARMA academic related the some that the reported collaborations in $X translational as be
from customers milestones It of and early programs. as our SPL the nature made from model we in customers' the are partners predicting customers. As MaxCyte regulatory of therapy to economics had pipeline. our earlier again, revenue of anticipated, recognized uniqueness difficulty customers and we the of the up than given clinical provides in and the our and revenue Doug does Surprises also downstream timing our predicated successes process, our of these participate encouraging, to value revenues view, cell face and demonstrate in CARMA some mentioned ability like we our were of related stage a SPL to testament these our customers' on earlier, are multiple this our that
milestone to we So We'll the time provide see do to until timing grow. visibility active programs pipelines near-term continues milestone partner the events into our as expect of to SPL partners to mature related and and revenue lumpy best continues we be of potential SPL SPL number expand. do as over for the that
potential through We by for given next approvals SPL encouraged, the the progress, of XX potential continue particularly and the clinic however, over and of the as to move CARMA XX, next related be enter the our even XX, couple partners months, revenue years. in
a over the revenue So broad-based long to more SPLs stream we the term. related anticipate growing and
almost the XX% margin milestone in XX% by with the difference P&L. quarter, revenue. the the quarter in Gross third Moving was down entirely driven being versus
margins were primarily $X.X $XX.X So operating million excluding relative last driven second This expenses milestone of related third the third were quarter to for of revenues, XXXX by gross headcount. of year. the million was the flat in quarter in increase compared quarter to increases Total XXXX.
increase As meaningful expanding are this many in were in CARMA-related resources driven as Doug in And we stock areas our reminder, business of expenses growth-based which in a price. primarily the -- well adding comp, mentioned, as no by the stock-based terms as quarter. was there in
business. and up opportunities advantage growth again, primary we Sales was XX% the plan about. organic is make year's to that's and year As to many the see next we've to a Doug continue this are the we marketing R&D quarter, in over increases quarter, in talked and investments over of that of goal XX% the And last was excluding saw years accelerate here up few ago. to areas over we expenses. mentioned, that And the CARMA-related making take
in talk ramp We manufacturing we XXXX, and about in marketing, in headcount expect can driven and more investment primarily additional development, investment product this by into continue to particularly this the to and around Q&A. overall investment operations,
end with healthy We into are very coming a of sheet. and the into XXXX balance XXXX
and end cash total debt. as short-term the quarter have third investments million the We no of and $XXX of of
year year where update given I see weighted year the revenue seeing has and to business drug revenue cell normally shifted in of by the fourth driven quarter, discovery the as mentioned, see, end our is success heavily therapy the typical guidance The partners this cycles. seasonality. and CapEx markets fiscal XXXX therapy more wanted We year-to-date. you're normally cell we which strength Lastly, our core we budget to of
trial, dynamics, trial some change As clinical progression bit you less correlated ahead encouraged seen in so are ramping little it partners progression can clinical these the year. that but timelines the to and for of clinical imagine in our seasonality we've a and by and does this of are we progression, trial
the quarter year the As prior the numbers million. $XX year result, greater of a expect total greater put we growth so This SPL of does the CARMA-related $XX where for of beat be revenue include in $XX roughly ahead to implies This million, growth target the would million. revenue. our than than for slightly versus
As expectations fourth saw to points quarters. it about we SPL think hard that you of second milestone recognition the relates data is pinpoint. to closer we timing magnitude our the to the and for quarter, would these what the CARMA-related Again, be first revenue in to can guide in
will it our year, revenue we CAGR I note just by above any So make as X-year meaningful sure caveat. companies Doug. business. the track same many back language that to continue comments XX% changes full encouraged to are turn making to the strength that, cautionary status that for and the in are our COVID. obviously it assuming to in I'll over cell we're quo wanted COVID. around therapy core relates I'm With We And
